AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03548220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablets.
Study NCT02049853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTproBNP measurement with point of care device Cobash232 in the POCT group
Study NCT01619072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol + referral
Description: 800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
Study NCT01619072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + referral
Description: Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
Study NCT04198909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways
Description: Electrocochleography is a technique that analyses the functionality of inner ear.
Study NCT04469634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessing antibody responses, neutralizing capacity and memory B-cell function
Description: Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
Study NCT00501657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg mane for 2 days
Study NCT00501657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg mane for 2 days
Study NCT06783231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying with the aggressor
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the aggressor' group will be asked to try to identify, understand and adopt the point of view of Lori (the perpetrator)
Study NCT06783231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Identifying with the victim
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the victim' group will be asked to try to identify, understand and adopt the point of view of Sophia (the victim)
Study NCT06783231 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The control group will be asked to pay attention to the story's details and to try and remember as much details as they can.
Study NCT01882413 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01246999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated Influenza vaccine
Description: 0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
Study NCT01246999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: .25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
Study NCT01246999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV followed by LAIV
Description: TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
Study NCT06548633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Vertebral Mobilisation
Description: The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
Study NCT04298879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI376
Description: IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
Study NCT01246999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LAIV followed by TIV
Description: LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
Study NCT01530581 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-PB Transplant
Description: G-PB Transplant
Study NCT01530581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-BM Transplant
Description: G-BM Transplant
Study NCT02288169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE
Description: We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
Study NCT02288169 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Support/Attention Control
Description: The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
Study NCT01606371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01606371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT03423810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
Study NCT02473965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks
Study NCT02473965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00733395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
Study NCT00733395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice
Description: Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
Study NCT01792531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training group
Description: The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
Study NCT01792531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment with focus on lifestyle
Description: The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
Study NCT01792531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training group with booster sessions
Description: Parent training group with additional booster sessions at 8-week intervals for the following year.
Study NCT00487825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab (investigational)
Description: Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study NCT00487825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study NCT00487825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Study NCT00487825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Study NCT01507649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based cognitive-behavioral intervention
Description: The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
Study NCT04339712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: In case of diagnosis of MAS treatment with anakinra
Study NCT04339712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: In case of diagnosis of immune dysregulation treatment with tocilizumab
Study NCT01562223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Study NCT05609604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Electric current will be delivered to the pre-frontal cortex for 30 minutes.
Study NCT05609604 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shame- No current
Study NCT04638556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA detection
Description: The lncRNAs in the plasma of three groups of patients will be tested.
Study NCT03180931 — intervention group
Intervention type: DEVICE
Intervention: Bioresorbable vascular scaffold
Description: No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants.
Study NCT03102749 — intervention group
Intervention type: OTHER
Intervention: metacholine provocation test and CT-scan low dose
Description: Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
Study NCT02646787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Virtual Reality
Description: The subject is actively engaged in using virtual reality during a painful burn wound care session.
Study NCT02646787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Virtual Reality
Description: The subject is passively engaged in using virtual reality during a painful burn wound care session.
Study NCT03126071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/m2,iv 15min,d1,q3w.
Study NCT03126071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan:250mg/m2,iv 90min,d1,q3w.
Study NCT03126071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
Study NCT03126071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab:75mg/kg,iv 30min,d1,q3w.
Study NCT02688764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 (Velphoro®)
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
Study NCT02688764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Acetate (Phoslyra®)
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
Study NCT01342445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Description: 30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
Study NCT01342445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03589157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)
Description: using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
Study NCT03589157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)
Description: using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
Study NCT01331707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity (Zotarolimus-eluting stent)
Description: Third generation drug-eluting stent
Study NCT01331707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element (Everolimus-eluting stent)
Description: Third generation drug-eluting stent
Study NCT03955588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: aCGH
Study NCT02102672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Study NCT01493115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT01493115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine - New formulation HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT02568397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT02568397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Administered orally
Study NCT01060397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention
Description: Frames motivational interviewing approach
Study NCT01060397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care
Study NCT04397211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-derived FFR
Description: The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~\*Criteria for revascularization: Angiography-derived FFR ≤ 0.80
Study NCT04397211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3\< MLA ≤ 4mm2 \& Plaque burden > 70%
Study NCT03514615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision
Description: A skin incision will be made on the medial aspect of the upper arm.
Study NCT03514615 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Incision
Description: A skin incision will be made on the medial aspect of the upper arm.
Study NCT03514615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active gel
Description: The incision site on one arm will be dosed with the active gel.
Study NCT04424472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Abdominal Ultrasonography
Study NCT02956707 — intervention group
Intervention type: OTHER
Intervention: No pre-operative steroids
Description: Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
Study NCT00452153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Characterization Legionnella
Description: * Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region
Study NCT03514615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The incision site on the other arm will be dosed with placebo gel.
Study NCT01378806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise education and coping skills training
Description: A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
Study NCT05869396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: Bedside echocardiography
Study NCT04131582 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin and Empagliflozin + metformin
Description: Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT04131582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT02051088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization with drug-eluting technology
Description: Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
Study NCT02051088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization without drug-eluting technology
Description: Endovascular intervention without using drug-eluting balloons or stents
Study NCT02051088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloons and/or drug-eluting stents